Shields Health Solutions leaders say GLP-1 discontinuation is a support problem, not a medication problem, and pharmacist-led care can help close it.
|Articles|November 1, 1997
Supplements and Featured Publications
- New and Emerging Therapies in the Treatment of Type 2 Diabetes
- Volume 3
- Issue 10 Suppl
Selected Abstracts
Advertisement
Articles in this issue
almost 29 years ago
Goals and Objectivesalmost 29 years ago
Participating Facultyalmost 29 years ago
Declaring War on Diabetes: New Strategies for Old Battlesalmost 29 years ago
Diabetes: New Insights, Innovative Approachesalmost 29 years ago
Roundtable Discussions - Diabetes Prevalence, Development and Progressionalmost 29 years ago
Roundtable Discussions - Diabetes Management Techniquesalmost 29 years ago
CME Quizalmost 29 years ago
BibliographyAdvertisement
Related to this article
Claims data also tied the combination to better adherence and fewer hospital admissions, including in bipolar I disorder, vs olanzapine alone.
A review finds vertigo is an underrecognized sign of multiple sclerosis (MS) relapse and that the HINTS exam cannot distinguish an MS attack from stroke.
Most Medicaid unwinding losses were procedural. mPulse's SriVani Ganti explains how plans can keep eligible members.
Youths with depression had about twice the odds of prescription drug misuse and 4 times the odds of use disorder, compared with peers without depression.
University of Virginia Health is tracking efgartigimod durability in generalized myasthenia gravis and how pharmacists help patients get past barriers.
NCCN now lists the brain-penetrant ROS1 inhibitor after progression on earlier TKIs, including as a preferred option for symptomatic brain progression.
KFF finds 4.3 million Medicare beneficiaries will lose their MA or stand-alone Part D plans at the end of 2026, as PDP options keep shrinking.
Advertisement
Advertisement
Trending on AJMC
1
Higher Ropeginterferon Alfa-2b Exposure Liked to JAK2 Reductions in ET
2
Medicare Plan Terminations Hit 4.3 Million as Part D Market Shrinks
3
FDA Approves Talazoparib Plus Enzalutamide for HRR-Mutated mHSPC
4
Menin Inhibitors in AML: In NYC, Experts Map the Path From Academic Centers to Community Care
5